Program
Human Papillomavirus Recombinant Vaccine nonavalent
Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.
Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.
Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 207 open or running | phase 3since Jul 21, 2009 | Jul 21, 2009 | Jan 15, 2027phase 3 · NCT04199689 |
| Shanghai Bovax Biotechnologyits history only | 21 open or running | phase 3since Jun 8, 2020 | Jun 8, 2020 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only | 11 open or running | early phase 1since Apr 28, 2025 | Apr 28, 2025 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Mar 16, 2020 | Mar 16, 2020 | none ahead |
| Xiamen Innovax Biotech | 11 open or running | phase 4since Jun 16, 2026 | Jun 16, 2026 | Feb 28, 2027phase 4 · NCT07668271 |
Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Xiamen Innovax Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2026First study: phase 4 study in Infection by Human Papilloma VirusFirst studyNCT07668271 · 720 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 4 study in Infection by Human Papilloma VirusNCT07668271
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
The one study Xiamen Innovax Biotech leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07668271Infection by Human Papilloma Virus · China | 4 | Recruiting | Feb 28, 2027 | 720 |
How it is read
Names in the registry
- “V503”, 10 entries
- “9vHPV Vaccine”, 5 entries
- “9vHPV vaccine”, 5 entries
- “9-valent HPV vaccine (Cecolin 9)”, 1 entry
- “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry
Conditions, from the studies’ own filings
- Papillomavirus Infections, 13 studies
- Condylomata Acuminata, 5 studies
- Uterine Cervical Neoplasms, 4 studies
- Papilloma, 1 study
- Dengue, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.